Who Paid My Doc
David Huang
Pittsburgh, PA Medical Doctor
NPI 1356315774 CMS profile 1305024
300 Halket St, Magee-Womens Hospital, Pittsburgh, PA 15213
General payments
$9,712
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$8,879
Through program year 2025, David Huang of Pittsburgh, PA is reported in the CMS Open Payments database as having received $9,712 across 20 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,879 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,168 | 4 | |
| 2024 | General | $182 | 1 | |
| 2021 | General | $2,235 | 2 | |
| 2020 | General | $450 | 1 | |
| 2019 | General | $2,676 | 12 |
Beside peers
- David Huang
- Pennsylvania median
- Middle half of Pennsylvania
- National median
In program year 2025, general payments to David Huang were reported at $4,168. Among 44,217 Pennsylvania profiles paid that year, the median was $168 and the middle half received between $50 and $597.
Show as a table
| Year | David Huang | Pennsylvania median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,676 | $156 | $46–$628 | $163 |
| 2020 | $450 | $109 | $33–$381 | $114 |
| 2021 | $2,235 | $125 | $35–$469 | $132 |
| 2022 | $0 | $136 | $40–$499 | $149 |
| 2023 | $0 | $147 | $46–$523 | $160 |
| 2024 | $182 | $156 | $46–$568 | $164 |
| 2025 | $4,168 | $168 | $50–$597 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$18,528
Medicare patients
43
Services billed
148
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 70% | |
| Diabetes | 60% | |
| Ischemic heart disease | 56% | |
| Arthritis | 49% | |
| Heart failure | 42% | |
| COPD | 42% | |
| Atrial fibrillation | 33% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
20 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.